• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 18, 2016

View Archived Issues

Financings

Mabvax Therapeutics Holdings Inc., of San Diego, priced a public offering o $8.625 million of common stock and series F preferred stock at $4.81 per share of common stock or series F preferred stock. Laidlaw & Co. (UK) Ltd. acted as the sole book-running manager. Underwriters have a 45-day option to purchase up to an aggregate of 169,179 additional shares (with additional class A warrants and class B warrants) solely to cover overallotments. Read More

Regulatory front

The FDA sent a warning letter to Zhejiang Medicine Co. Ltd. referencing data and quality testing issues at its API facility in Xinchang, China. During an inspection at the plant more than a year ago, FDA investigators observed staff conducting multiple unofficial gas chromatography (GC) analyses of samples for residual solvents and recording the data in separate folders before conducting the officially reported sample analyses. The unofficial data, some of which showed large peaks, were not used to evaluate the quality of the API or to make batch release decisions. . Read More

Other news to note

The Female Health Co. (FHC), of Chicago, and Aspen Park Pharmaceuticals Inc. (APP), of New York, said the FDA agreed to an expedited regulatory pathway for APP's tamsulosis DRS (delayed-release sachet) for benign prostatic hyperplasia under the 505(b)(2) pathway. A three-week bioequivalence study will be initiated in the fourth quarter, with plans to submit an NDA in 2017. FHC and APP inked a merger agreement earlier this year. Read More

Roche wins come-out roll with Eleven as other talks turn up cold table in IL-6

In January, after Eleven Biotherapeutics Inc. disclosed mixed phase III data in severe allergic conjunctivitis with the interleukin-1 (IL-1) signaling inhibitor EBI-005 (isunakinra) – which also proved a dud in the late-stage experiment for dry eye disease in May 2015 – the stock took a 77 percent hit and Wall Street retreated. Read More

Avelas to advance cancer imaging agent with $20M series C

Avelas Biosciences Inc. raised $20 million in a series C financing that the company will use to carry its cancer imaging agent, AVB-620, into late-stage trials while also developing new targeted cancer therapies that leverage its Activatable Cell Penetrating Peptide platform. Read More

Indivior stock rises on phase III data in opioid dependence

DUBLIN – Shares in Indivior plc rose more than 21 percent to an all-time high during early trading Wednesday on news that RBP-6000, a once-per-month depot injection of buprenorphine, hit the primary endpoint of a phase III trial in patients with opioid use disorder. Read More

Genetic homogeneity in sequenced individuals can lead to health disparities

As the Exome Aggregation Consortium (Exac) published findings from their deep dive into the genetic well Wednesday, another set of scientists published a cautionary tale illustrating the sort of clinical problem that Exac's Exome Sequencing Project (ESP) can address. (See story in this issue.) Read More

Exome yielding its secrets: Exac database project IDs gene variants

LONDON – The power of big data in human biology is exemplified in a paper published Wednesday in Nature analyzing genetic variation in the protein-coding exomes of 60,706 healthy volunteers. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe